Stock Forecast

  Scholar Rock Holding Corporation ( SRRK) Stock. Should you Buy or Sell?    $ 9.18

-0.20 (-2.23 %)



Scholar Rock Holding Corporation Analysis

Updated on 10-09-2022
Symbol SRRK
Price $9.18
Beta 0.629
Volume Avg. $1.27 M
Market Cap $474.06 M
52 Week Range $4.325 - $42.54


Scholar Rock Holding Corporation opened the day at $9.18 which is -2.23 % on yesterday's close. Scholar Rock Holding Corporation has a 52 week high of $42.54 and 52 week low of $4.325, which is a difference of $38.215. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $474.06 M and total net profit is $18816000 which means the company is trading at 25.19 times profit to market capitalization. Theoretically, if you were to buy Scholar Rock Holding Corporation for $474.06 M, it would take 15 years to get your money back. Scholar Rock Holding Corporation are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




Scholar Rock Holding Corporation Stock Forecast - Is Scholar Rock Holding Corporation a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreBuy
Overall RecommendationNeutral

Growth and Value


PE Ratio -4.271
Dividend Yiel 0.000
Net Profit Margin -2.314


Valuing Scholar Rock Holding Corporation


Price Book Value Ratio 1.160 Price To Book Ratio 1.160
Price To Sales Ratio 9.884 Price Earnings Ratio -4.271


How liquid is Scholar Rock Holding Corporation


Current Ratio 9.689
Quick Ratio 9.230


Debt


Debt Ratio 0.223 Debt Equity Ratio 0.287
Long Term Debt To Capitalization 0.142 Total Debt To Capitalization 0.183



Latest news about Scholar Rock Holding Corporation


Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.

Date : 15/07/2022

Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?

The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Date : 11/07/2022

Why Scholar Rock Stock Flew High Today

A venture capital group significantly increased its stake in the company.

Date : 27/06/2022

How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%

The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Date : 24/06/2022

Why Scholar Rock Shares Are Trading Higher Today

Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months.

Date : 17/06/2022





About Scholar Rock Holding Corporation


CEO : Dr. Nagesh Mahanthappa
Sector : Healthcare
Industry : Biotechnology

Website : https://scholarrock.com

Exchange : NASDAQ Global Select

Description :

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.


My Newsletter

Sign Up For Updates & Newsletters